Compare Cassava Sciences Inc (FLNA) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Cassava Sciences Inc trades at $0.84 (market cap $39.40M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 641.4× Cassava Sciences Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| FLNA | RPRX | |
|---|---|---|
Market Cap | $39.40M | $25.27B |
Volume | 759,018 | 3,671,183 |
Sector | Health | Health |
52-Week High | $4.64 | $63.96 |
52-Week Low | $0.68 | $35.44 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | -$43.28M | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
